Allergic Asthma - Pipeline Review, H1 2014

  • Share on Google+

Global Markets Direct

2014 Jun 30

150 Pages (PDF)




Allergic Asthma - Pipeline Review, H1 2014

Summary

Global Markets Directs, Allergic Asthma - Pipeline Review, H1 2014, provides an overview of the Allergic Asthmas therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Allergic Asthma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Allergic Asthma and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Allergic Asthma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Allergic Asthma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Allergic Asthma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Allergic Asthma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Allergic Asthma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Allergic Asthma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Allergic Asthma Overview 10
Therapeutics Development 11
Pipeline Products for Allergic Asthma - Overview 11
Pipeline Products for Allergic Asthma - Comparative Analysis 12
Allergic Asthma - Therapeutics under Development by Companies 13
Allergic Asthma - Therapeutics under Investigation by Universities/Institutes 16
Allergic Asthma - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Unknown Stage Products 20
Allergic Asthma - Products under Development by Companies 21
Allergic Asthma - Products under Investigation by Universities/Institutes 23
Allergic Asthma - Companies Involved in Therapeutics Development 24
Boehringer Ingelheim GmbH 24
F. Hoffmann-La Roche Ltd. 25
Genentech, Inc. 26
BioTech Tools 27
Dainippon Sumitomo Pharma Co., Ltd. 28
Infinity Pharmaceuticals, Inc. 29
Novartis AG 30
ALK-Abello A/S 31
DBV Technologies SA 32
Nuvo Research Inc. 33
Portola Pharmaceuticals, Inc. 34
Array BioPharma Inc. 35
Stallergenes S.A. 36
Panacea Biotec Limited 37
Marinomed Biotechnologie GmbH 38
Allergopharma Joachim Ganzer KG 39
Pulmatrix, Inc. 40
Kineta, Inc. 41
AIM Therapeutics Inc. 42
Asmacure Ltee 43
NeoPharm Co., Ltd. 44
Aslan Pharmaceuticals Pte. Ltd. 45
Protectimmun GmbH 46
sterna biologicals Gmbh & Co KG 47
S-TARget therapeutics GmbH 48
Peptinnovate Limited 49
Allergic Asthma - Therapeutics Assessment 50
Assessment by Monotherapy Products 50
Assessment by Combination Products 51
Assessment by Target 52
Assessment by Mechanism of Action 55
Assessment by Route of Administration 58
Assessment by Molecule Type 60
Drug Profiles 62
allergenic pollen extract of timothy - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
omalizumab - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
MK-8237 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
MK-7243 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Acaroid - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
DSP-3025 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
AIM-102 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
S-524101 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
ASM-024 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
quilizumab - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
duvelisib - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
fevipiprant - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
ARRY-502 - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
QGE-031 - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
SB-010 - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
PRT-2607 - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
FX-141-L - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
FX-87-L - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
ShK-186 - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
omalizumab biosimilar - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
SG-100 - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
(fluticasone propionate + salmeterol xinafoate) - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
Viaskin House Dust Mite - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
Lactococcus lactis G121 - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
Arabinogalactan - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
MAM-06301 - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
Small Molecules to Inhibit C-Rel for Central Nervous System, Musculoskeletal, Respiratory and Metabolic Disorders - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
PIN-201601 - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
ASLAN-004 - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
Synthetic Peptide for Multiple Sclerosis, Colitis and Allergic Asthma - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
hdm-ASIT - Drug Profile 105
Product Description 105
Mechanism of Action 105
R&D Progress 105
Vaccine for Allergic Rhinitis and Allergic Asthama - Drug Profile 106
Product Description 106
Mechanism of Action 106
R&D Progress 106
Small Molecules for Allergic Asthma - Drug Profile 107
Product Description 107
Mechanism of Action 107
R&D Progress 107
Small Molecule for Allergic Asthma - Drug Profile 108
Product Description 108
Mechanism of Action 108
R&D Progress 108
WF-10 - Drug Profile 109
Product Description 109
Mechanism of Action 109
R&D Progress 109
Small Molecules to Inhibit CaMKII for Allergic Asthma - Drug Profile 111
Product Description 111
Mechanism of Action 111
R&D Progress 111
E-3.56 - Drug Profile 112
Product Description 112
Mechanism of Action 112
R&D Progress 112
omalizumab biosmiliar - Drug Profile 113
Product Description 113
Mechanism of Action 113
R&D Progress 113
Allergic Asthma - Recent Pipeline Updates 114
Allergic Asthma - Dormant Projects 137
Allergic Asthma - Discontinued Products 138
Allergic Asthma - Product Development Milestones 139
Featured News & Press Releases 139
Dec 16, 2013: Soliris Concentrated Solution for Intravenous Infusion by Alexion: Recall - Visible Particles 139
Jul 11, 2013: Positive results from pivotal Phase III trial of new allergy immunotherapy tablet against house dust mite-induced allergic asthma 139
May 21, 2013: Sanofi And Regeneron Pharma Announce Publication Of Positive Phase IIa Results Of Dupilumab In Asthma In New England Journal Of Medicine 141
May 16, 2013: Asmacure Announces Presentation Of Four Posters On ASM-024 At ATS 2013 International Conference 142
May 14, 2013: Nuvo Research Secures US Patent For Treatment Of Allergic Rhinitis And Allergic Asthma With WF10 143
Apr 23, 2013: Novartis's Asthma Drug Xolair Obtains Recommendation From NICE 143
Apr 15, 2013: Asmacure Doses First Subjects With ASM-024 Dry Powder For Inhalation 145
Apr 08, 2013: S-TARget Achieves In Vivo Proof Of Concept For Its Allergy Vaccine SG100 146
Mar 27, 2013: Merck Announces FDA Acceptance Of Biologics License Application For Investigational Grass Pollen Allergy Immunotherapy Tablet 146
Mar 06, 2013: Novartis's Omalizumab Receives NICE Recommendation For Treatment Of Allergic Asthma 147
Appendix 149
Methodology 149
Coverage 149
Secondary Research 149
Primary Research 149
Expert Panel Validation 149
Contact Us 150
Disclaimer 150
Boehringer Ingelheim GmbH
F. Hoffmann-La Roche Ltd.
Genentech, Inc.
BioTech Tools
Dainippon Sumitomo Pharma Co., Ltd.
Infinity Pharmaceuticals, Inc.
Novartis AG
ALK-Abello A/S
DBV Technologies SA
Nuvo Research Inc.
Portola Pharmaceuticals, Inc.
Array BioPharma Inc.
Stallergenes S.A.
Panacea Biotec Limited
Marinomed Biotechnologie GmbH
Allergopharma Joachim Ganzer KG
Pulmatrix, Inc.
Kineta, Inc.
AIM Therapeutics Inc.
Asmacure Ltee
NeoPharm Co., Ltd.
Aslan Pharmaceuticals Pte. Ltd.
Protectimmun GmbH
sterna biologicals Gmbh & Co KG
S-TARget therapeutics GmbH
Peptinnovate Limited				
Full Name
Email
Job Title
Mobile
Your Requirement
Full Name
Email
Job Title
Mobile
Your Requirement